| 1  | Efficacy of multilevel exercise programmes with different intensities on development  |
|----|---|
| 2  | and metabolic homeostasis in overweight and obese children: study protocol for a  |
| 3  | randomized controlled trial   |
| 4  |   |
| 5  | Yimin Zhao <sup>1, #</sup> , Chao Liu <sup>2, #</sup> , Jiaxing Wang <sup>2</sup> , Yangong Liu <sup>2</sup> , Haiyi Yu <sup>2</sup> , Tianqi Chang <sup>2</sup> , Chenyu           |
| 6  | Fan <sup>2</sup> , Wenxiu Wang <sup>1</sup> , Yueying Li <sup>1</sup> , Hu Wang <sup>2</sup> , Yuzhou Xue <sup>2</sup> , Wei Zhao <sup>2, 4</sup> , Chuan Ren <sup>2</sup> , Ligang |
| 7  | Cui <sup>3</sup> , Xinheng Feng <sup>2</sup> , He Huang <sup>8</sup> , Dongwei Fan <sup>5</sup> , Xiang Yao <sup>6</sup> , Tongyan Han <sup>7</sup> , Tao Huang <sup>1</sup> , and  |
| 8  | Ming Xu <sup>2,*</sup>  |
| 9  |   |
| 10 | <sup>1</sup> Department of Epidemiology and Biostatistics, School of Public Health, Peking University,  |
| 11 | Beijing, China;   |
| 12 | <sup>2</sup> Department of Cardiology, Institute of Vascular Medicine, NHC Key Laboratory of  |
| 13 | Cardiovascular Molecular Biology and Regulatory Peptides, Key Laboratory of Molecular   |
| 14 | Cardiovascular Science, Ministry of Education, Beijing Key Laboratory of Cardiovascular   |
| 15 | Receptors Research, Peking University Third Hospital, Beijing, China;   |
| 16 | <sup>3</sup> Department of Ultrasound, Peking University Third Hospital, Beijing, China;  |
| 17 | <sup>4</sup> Physical Examination Center, Peking University Third Hospital, Beijing, China;   |
| 18 | <sup>5</sup> Department of Orthopedics, Peking University Third Hospital, Beijing, China;   |
| 19 | <sup>6</sup> School of Psychological and Cognitive Sciences, Peking University, Beijing, China;   |
| 20 | <sup>7</sup> Department of Pediatrics, Peking University Third Hospital, Beijing, China.  |
| 21 | <sup>8</sup> Shanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and  |
| 22 | Integrative Biology, Shanghai, China  |

- 23
- <sup>#</sup>Yimin Zhao and Chao Liu contributed equally to this work.
- 25
- 26 Corresponding authors:
- 27 Ming Xu, MD, PhD
- 28 Department of Cardiology, Institute of Vascular Medicine, NHC Key Laboratory of
- 29 Cardiovascular Molecular Biology and Regulatory Peptides, Key Laboratory of Molecular
- 30 Cardiovascular Science, Ministry of Education, Beijing Key Laboratory of Cardiovascular
- 31 Receptors Research, Peking University Third Hospital, Beijing, China
- 32 Email: xuminghi@bjmu.edu.cn

# 33 Abstract

| 34 | Background: | The prevalence of | f childhood obesity is | rapidly increasing | worldwide. Exercise |
|----|-------------|-------------------|------------------------|--------------------|---------------------|
|----|-------------|-------------------|------------------------|--------------------|---------------------|

35 has been suggested as the primary approach to manage body weight, but an effective

- 36 exercise program tailored for school-age children is still lacking.
- 37 **Objective:** This trial aims to evaluate the efficacy of a novel multilevel (children, families, and
- 38 schools)-coordinated exercise programmes with different intensities on adiposity and
- 39 development among overweight and obese school-age children. It also aims to elucidate the
- 40 complex interplays between the exercise interventions, multi-omic biomarkers, development,
- 41 and metabolic homeostasis.
- 42 **Methods:** This is a multilevel -coordinated two-stage randomized double-blind controlled trial,

43 comprising 366 overweight and obese children aged between 8 and 12 years from two

- 44 elementary schools in Beijing, China. The novel multilevel exercise programs involve families
- 45 and schools monitoring children's exercise and diet via a specially designed smartphone

46 application. The children will be randomly assigned to receive three school-based exercise

47 programmes (exercise intervention stage), namely low-intensity exercise, moderate-intensity

48 exercise, and intermittent vigorous exercise, for 12 weeks, followed by a 9-month

- 49 post-intervention follow-up (follow-up stage). The primary outcomes of this trial are the
- 50 changes in adiposity, development, and metabolic homeostasis during the two stages. The
- 51 secondary outcomes include but are not restricted to genomics and changes in blood

52 metabolomics, gut microbiota, and exercise performance.

53 **Discussion:** This trial has been approved by the ethics committee of Peking University Third

54 Hospital (ethnic approval number 2021-283-08). The findings of this trial will help establish

- 55 specialized multilevel coordinated school-based exercise programmes for overweight and
- 56 obese school-age children in China and quantitatively and qualitatively evaluate the efficacy
- 57 of the novel interventions.
- 58 Trial registration: This trial was prospectively registered at ClinicalTrials.gov with the
- 59 identifier of NCT04984005 on July 21, 2021.
- 60

# 61 Introduction

| 62 | The prevalence of childhood obesity is rapidly increasing worldwide. According to recent data,                |
|----|---|
| 63 | the number of obese children and adolescents has increased from 11 million in 1975 to 124                     |
| 64 | million in 2016. <sup>12</sup> This issue is becoming particularly prevalent in developing countries such     |
| 65 | as China, where the prevalence of childhood obesity and related non-communicable chronic                      |
| 66 | diseases is rising rapidly. <sup>3</sup> It is projected that by 2030, 6.64 million children under the age of |
| 67 | seven, and 18.91 million children over the age of seven in China, will be obese. <sup>45</sup> In Beijing,    |
| 68 | the prevalence of overweight and obesity was found to be 17.6% and 29.1% in boys and 17.6%                    |
| 69 | and 18.0% in girls aged between 6 to 18 years, respectively. <sup>5</sup>                                     |
| 70 |   |
| 71 | Childhood obesity has been linked to an increased risk of type 2 diabetes, heart disease, and                 |
| 72 | chronic kidney disease in later life. <sup>6-10</sup> While exercise intervention remains the primary         |
| 73 | approach for managing body weight, it may not achieve sustained desirable body weight                         |
| 74 | reduction on its own for obese children who also have to manage academic stress. <sup>11-14</sup> Indeed,     |
| 75 | a recent multicomponent lifestyle intervention successfully reduced adiposity and obesity                     |
| 76 | prevalence among children. <sup>4</sup> However, whether the involvement of schools and families could        |
| 77 | improve the effectiveness of exercise intervention among school-age obese children is still                   |
| 78 | less studied. <sup>15</sup> Notably, the parents and teachers may hold the opinions that strict exercise      |
| 79 | intervention may impede growth and development and academic performance of the children,                      |
| 80 | thus reducing the effectiveness of exercise. In addition, it remains unknown whether a more                   |
| 81 | intense exercise programme would bring about additional health benefits in terms of                           |
| 82 | development and metabolic homeostasis beyond body weight during puberty for obese                             |

5 / 25

| 83 | childrer | ۱ <sup>1</sup> | 14 |
|----|----------|----------------|----|
| 00 | Grindron |                |    |

| 85  | In this study, we aim to compare the effects of multilevel-coordinated exercise programmes       |
|-----|--|
| 86  | with different intensities on adiposity, development, and metabolic homeostasis, as well as      |
| 87  | related mechanisms. Specifically, we aim to determine which exercise programme is more           |
| 88  | effective in reducing body weight and improving development and metabolic homeostasis            |
| 89  | among overweight and obese children, as well as identifying the factors that mediate             |
| 90  | exercise-induced changes in these areas. Additionally, we aim to establish a regionally          |
| 91  | representative school-family-hospital evaluation model for exercise intervention.                |
| 92  |  |
| 93  | Method and Analysis  |
| 94  | Trial design   |
| 95  | This is a multilevel coordinated (children, families, and schools) two-stage 12-month            |
| 96  | three-arm randomized double-blind controlled trial.  |
| 97  |  |
| 98  | Methods: Participants, interventions, and outcomes   |
| 99  | This protocol is reported following the guidelines of the Standard Protocol Items:               |
| 100 | Recommendations for Interventional Trials (SPIRIT) 2013 Statement. <sup>16</sup>                 |
| 101 |  |
| 102 | Study setting  |
| 103 | This trial will be conducted in two government-funded elementary schools in Beijing, the         |
| 104 | capital city of China. The steering committee of this study included paediatricians, physicians, |

- 105 epidemiologists, and statisticians from Peking University Third Hospital and School of Public
- 106 Health at Peking University. All study procedures will be performed in accordance with the
- 107 Declaration of Helsinki.
- 108
- 109 Eligibility criteria
- 110 Eligible participants must meet the following inclusion criteria:
- 111 1) overweight or obese (see **Table 1** for age- and sex-specific BMI cutoff points);
- 112 2) 8 to 12 years old;
- 113 3) did not participate in any weight loss programmes, including medication, exercise, and
- 114 lifestyle modification, within the last three months before baseline assessment;
- 115 4) provide written informed consent by both themselves and their statutory guardians.
- 116
- 117 Participants will be excluded if they have any of the following conditions:
- 118 1) have any severe chronic disease, including asthma, cardiovascular disease, and cancer.
- 119 2) have drug-induced secondary obesity;
- 120 3) have Cushing syndrome, Prader-Willi syndrome, or other medical conditions that may
- 121 lead to obesity;
- 122 4) have intellectual, mental, or behavioural disorders;
- 123 5) feel difficulty communicating with physical education (PE) teachers, paediatricians, and
- 124 physicians;
- 125 6) have any other conditions that may prevent exercising safely, which will be assessed by
- 126 paediatricians and physicians.

#### 127

#### 128 Who will take informed consent?

- 129 A group of research staff, including paediatricians and physicians, will collect written informed
- 130 consent from both children and their statutory guardians before evaluating the eligibility of
- 131 potential participants. During the consent process, potentially eligible participants and their
- 132 parents will be notified that this trial will require the collection of fasting blood, urine, and
- 133 faeces samples.
- 134

## 135 Interventions

### 136 Explanation for the choice of comparators

137 Eligible participants will be randomly assigned into three groups receiving low-intensity

138 exercise, moderate-intensity exercise, and intermittent vigorous exercise, respectively. The

139 low-intensity exercise is chosen as the comparator because exercise intervention, even at a

140 low intensity, has been proven effective in improving energy expenditure and cardiometabolic

- 141 health among children and adolescents. The novel intervention programmes emphazie the
- 142 involvement of family and school to assist children's exercise and food intake using a
- specifically designed smartphone application. The health educators, the pediatrician in the
- school hospital, will be trained by the project staff before the intervention. During the
- 145 intervention, the health educator will deliver two health education sessions, including exercise
- and healthy eating, to children every month. Family members and school PE teachers at each
- site will be separately invited to attend the health education sessions two times per month,
- 148 where the project staff shared the information on children's exercise performance and

8 / 25

strengthened the family and school involvement to assist children's exercise.

150

### 151 Intervention description

- 152 The levels of intensity will be determined according to the percentages of heart rate reserve
- 153 (HRR) during exercise, which is calculated by deducting the resting heart rate (HR<sub>resting</sub>) from

154 the maximum heart rate  $(HR_{max})$ .<sup>17 18</sup> The  $HR_{resting}$  and the  $HR_{max}$  will be evaluated on a

155 COSMED Quark PFT pulmonary function testing system in Peking University Third Hospital at

156 baseline.

| 158 | All  | participants will engage in a school-based exercise programme, instructed by PE teachers,                |
|-----|------|--|
| 159 | at t | he frequency of 30 minutes/time $\times$ two times/day $\times$ three days/week for 12 weeks. Each       |
| 160 | 30-  | minute exercise will comprise a 7-minute warm-up session, a 16-minute exercise session,                  |
| 161 | and  | a 7-minute cool-down session. In the warm-up and cool-down sessions, all groups of                       |
| 162 | par  | ticipants will do walking and stretching exercises, including arm circles, overhead arm                  |
| 163 | rea  | ches, and hip rotations, to reach a target heart rate of around $0.3 \times HRR + HR_{resting}$ . During |
| 164 | the  | 16-minute exercise session:  |
| 165 | 1)   | for the low-intensity exercise group, the participants will be instructed to take 800-meter              |
| 166 |      | quick walking and high knees to reach a target heart rate between 0.3 $\times$ HRR + HR $_{\rm resting}$ |
| 167 |      | and 0.4 × HRR + HR <sub>resting</sub> ;  |
| 168 | 2)   | for the moderate-intensity exercise group, the participants will be instructed to take                   |
| 169 |      | 30-meter S-shaped quick walking, 30-meter S-shaped running, and 800-meter alternating                    |
| 170 |      | between running and walking to reach a target heart rate between 0.4 $\times$ HRR + HR $_{\rm resting}$  |

| 171 | and 0.69 × HRR + HR <sub>restin</sub> | ng; |
|-----|---------------------------------------|-----|
|-----|---------------------------------------|-----|

| 172 | 3) for the intermittent vigorous exercise group, the participants will be instructed to take             |
|-----|--|
| 173 | various 30-second jumping and quick running activities to reach a target heart rate                      |
| 174 | between 0.7× HRR + HR <sub>resting</sub> and 0.85 × HRR + HR <sub>resting</sub> , divided by a 60-second |
| 175 | relaxation above 0.6× HRR + HR <sub>resting.</sub>   |
| 176 |  |
| 177 | In the 2-week run-in period prior to intervention period, all participants will receive the same         |
| 178 | low-intensity exercise intervention as described above.  |
| 179 |  |
| 180 | Criteria for discontinuing or modifying allocated interventions  |
| 181 | We allow participants to discontinue the exercise intervention at any time for any reason. The           |
| 182 | research staff will document the reasons for dropping out if provided by the participants. We            |
| 183 | will not recruit new participants to fill the vacancy after the implementation of the exercise           |
| 184 | intervention.  |
| 185 |  |
| 186 | Strategies to improve adherence to interventions   |
| 187 | Participants will be instructed to wear a calibrated smartwatch (Huawei Band 6) during the               |
| 188 | run-in and intervention stages, which is provided by Huawei Technologies for free. During                |
| 189 | each 30-minute exercise session, the smartwatch will return 30 reads of real-time heart rate at          |
| 190 | a 1-minute interval. Adherence to the exercise programme is assessed by counting the                     |
| 191 | real-time heart rate reads that are within the target range for each participant. We assume that         |
| 192 | all 16 reads collected during the 16-minute exercise session are located within the target               |

|--|

- 194 complete the 12-week exercise intervention with a gift, including a pen and pencil box.
- 195

### 196 Relevant concomitant care permitted or prohibited during the trial

- 197 During the 2-week run-in period and 12-week exercise intervention period, all participants will
- 198 be instructed to maintain their usual physical activity and diet using the specifically designed
- smartphone application. We will monitor their diet compositions via a three-day dietary recall,
- and the nutrient intake will be analyzed according to China Food Composition Tables.<sup>19</sup> We
- 201 will assess their physical activity, excluding exercise intervention, via the Huawei band 6.
- 202 These two questionnaires will be performed by trained research staff face-to-face. In addition,
- 203 participants and their parents will receive notifications via a mobile phone application, which
- will notify the participants to maintain their usual diet and physical activity.

205

### 206 **Provisions for post-trial care**

- 207 We will implement a 9-month post-intervention follow-up to observe the dynamic changes in
- 208 adiposity among the participants.
- 209
- 210 Outcomes
- 211 **Primary outcomes**
- 212 The primary outcomes of this trial are the changes in adiposity and biomarkers of
- 213 development and homeostasis, including anthropometric measurements, sexual hormones,
- body compositions, cardiopulmonary functions, and biochemical measurements.

## 215

# 216 Secondary outcomes

- 217 Secondary outcomes include changes in:
- 218 1. Exercise performance;
- 219 2. Hepatic hemodynamic index;
- 220 3. Bone mineral density;
- 221 4. Inflammatory biomarkers;
- 222 5. Thyroid function;
- 223 6. Oxidative stress biomarkers;
- 224 7. Oral and gut microbiota;
- 225 8. Blood and faecal metabolomics;
- 226 9. Flow-mediated dilation
- 227 10. Attention performance;
- 228 11. Sleep quality;
- 229 12. Diets and nutrients;
- 230 13. Whole genome sequencing;
- 231 14. Viromics;
- 232 15. Proteomics;
- 233 16. Volatile organic compounds in breath;
- 234

# 235 Participant timeline

**Figure 1** shows the schedule of enrollment, allocation, interventions, and assessments.

# 237

#### 238 Sample size

239 We estimated the sample size using the following equation:

$$N_{d} = \frac{1641.6 \times \lambda}{(sin^{-1}\sqrt{p_{max}} - sin^{-1}\sqrt{p_{min}})^{2}}$$

240 , where  $N_d$  is the minimum sample size,  $P_{max}$  and  $P_{min}$  are the highest and lowest cure rates,

and  $\lambda$  depends on  $\alpha$ ,  $\beta$ , and degree of freedom. In this trial,  $\alpha$  is 0.05,  $\beta$  is 0.1, and the degree

of freedom is 2. Thereby,  $\lambda$  is 12.65. We assumed that 65%, 50%, and 40% of overweight and

243 obese participants that receive low-intensity exercise, moderate-intensity exercise, and

intermittent vigorous exercise would successfully lower their body weight, achieving a healthy

BMI, respectively. A minimum sample size of 122 is required for each group accounting for a

246 10% drop-out rate. A total of 366 children will be included in this trial.

247

### 248 Recruitment

249 From January to March 2022, we included two elementary schools in Beijing by inviting the 250 school principals to participate in this trial. The two schools agreed with the study protocol. We 251 will recruit eligible participants, aged between 8 and 12 years, from seven school campuses. 252 All students and their parents (or their statutory guardians) will receive an advertisement for 253 this trial from the principal and their PE teachers. Potential eligible participants who provide 254 written informed consent by themselves and statutory guardians will be asked to complete a 255 nurse-administrated questionnaire concerning their health-related information and undergo a 256 physical examination according to standard operating procedure.

257

13 / 25

# 258 Assignment of interventions: allocation

## 259 Sequence generation

- 260 We will perform sex- and BMI-stratified randomization via computer-generated random
- 261 numbers.

262

## 263 Concealment mechanism

- 264 The participants will be randomized using a computer-generated random sequence, which will
- be sealed in an envelope until the end of this trial.

266

## 267 Implementation

- An independent statistician from the School of Public Health, Peking University, who will not
- 269 participate in recruitment, allocation, baseline assessment, and intervention, will conduct the
- 270 randomization.
- 271
- 272 Assignment of interventions: Blinding

# 273 Who will be blinded

- All participants, their parents, the PE teachers, the paediatricians, the physicians, and the
- 275 statisticians will be blinded to the allocation.

276

- 277 **Procedure for unblinding if needed**
- 278 Not applicable to this trial.

### 280 Data collection and management

#### 281 Plans for assessment and collection of outcomes

- All data will be collected and processed according to standard operating procedures. The
- 283 demographic information of participants will be collected at baseline. Trained nurses will
- 284 conduct the physical examination under the supervision of paediatricians. The biochemical
- 285 measurements will be conducted at the clinical laboratory of Peking University Third Hospital.
- 286 The oral and gut microbiota compositions will be analyzed using the QIIME2 pipeline
- 287 (https://qiime2.org). The metabolomics analysis will be conducted on a liquid
- 288 chromatography-electrospray ionization tandem mass spectrometry system (QTRAP 6500+
- system).<sup>20,21</sup> Diet will be evaluated via a 3-day diet recall at baseline and at the end of
- intervention period. Meanwhile, the participants will be instructed to take photo of meals to
- 291 facilitate nutrient intake analysis. Nutrients intake will be analzyed according to the China
- 292 Food Composition Tables by two independent investigators.<sup>19</sup>
- 293

#### 294 Plans to promote participant retention and complete follow-up

- 295 No other strategy is planned to promote participant retention and complete follow-up.
- 296

# 297 Data management

- A double entry and validation approach is planned for data management. The personal
- information and medical records of each participant will be kept in an individual folder and
- 300 stored in a secure storage area at the School of Public Health, Peking University. We will
- 301 return the results of the physical examination and laboratory biochemical measurement to

302 participants at the end of the exercise intervention/follow-up.

303

#### 304 Confidentiality

- 305 The personal information and medical records of participants will be treated as strictly
- 306 confidential. The research team will ensure the privacy and confidentiality of the personal
- 307 information and medical records of participants and store all data in an encrypted database
- 308 with all identifiers removed.

309

### 310 Plans for collection, laboratory evaluation and storage of biological specimens for

# 311 genetic or molecular analysis in this trial/future use

- 312 At baseline and the end of exercise intervention, 6 mL overnight fasting venous blood will be
- 313 collected by trained nurses from Peking University Third Hospital under the supervision of a
- 314 paediatrician. The participants will also provide urine and faeces samples. All biospecimens
- 315 will be immediately delivered to the clinical laboratory of Peking University Third Hospital and
- 316 stored at -80°C until analysis.

317

#### 318 Statistical methods

#### 319 Statistical methods for primary and secondary outcomes

- 320 Statistical analysis will be performed using Stata/MP version 17.0 by statisticians from Peking
- 321 University Health Science Center, which will not participate in participant enrollment,
- 322 allocation, and exercise intervention. The intention-to-treatment analysis will be used, which
- 323 includes all participants who complete the baseline assessment and is subject to

| 324 | randomization and exercise intervention. Between-group differences in continuous and               |
|-----|--|
| 325 | categorical variables at baseline will be analyzed using one-way analysis of variance and          |
| 326 | chi-square test, respectively. Within-group changes from baseline to the end of the                |
| 327 | intervention will be analyzed using paired t test for each group. Between-group differences of     |
| 328 | changes in the continuous variables will be analyzed using one-way ANOVA, one-way                  |
| 329 | analysis of covariance, or Mann-Whitney rank sum test when appropriate. Correlations of            |
| 330 | changes in continuous variables will be analyzed using Pearson's or Spearman's correlation         |
| 331 | analysis when appropriate. Statistical significance is set at $\alpha = 0.05$ .                    |
| 332 |  |
| 333 | Interim analyses   |
| 334 | No interim analysis will be performed due to the short duration of this trial.                     |
| 335 |  |
| 336 | Methods for additional analyses (e.g. subgroup analyses)   |
| 337 | In the sensitivity analysis, per protocol analysis is planned for participants that satisfactorily |
| 338 | complete both the baseline assessment and the two-stage intervention.                              |
| 339 |  |
| 340 | Methods in analysis to handle protocol non-adherence and any statistical methods to                |
| 341 | handle missing data  |
| 342 | Missing covariates will be estimated using the multiple imputation method.                         |
| 343 |  |
| 344 | Plans to give access to the full protocol, participant level-data and statistical code             |
| 345 | Access to the full study protocol, participant-level data, and statical codes will be granted for  |
|     | 17 / 25  |

346 authorized research staff and will not be publicly available.

347

#### 348 **Oversight and monitoring**

- 349 Composition of the coordinating centre and trial steering committee
- 350 The principal investigator (Prof. Ming Xu in the author list) has full responsibility for the design
- and conduct of the trial. The steering committee is responsible for agreeing on the final
- 352 protocol and reviewing the progress of the trial and potential changes to the protocol.
- 353

### 354 Composition of the data monitoring committee, its role and reporting structure

- 355 The data monitoring committee is composed of pedestrians and statisticians and is
- 356 responsible for assessing adherence to exercise intervention of each participant, monitoring
- 357 and reporting any adverse events during exercise intervention.

358

## 359 Adverse event reporting and harms

- 360 The research team is responsible for reporting any adverse events. During exercise
- intervention days, a field team comprised of a paediatrician (or a physician) and a research
- 362 staff from the site management organization will be sent to each school to deal with potential
- 363 adverse events. The PE teachers and other elementary school teachers will assist in
- 364 addressing potential anxiety and mood issues during exercise intervention. All severe adverse
- 365 events will be reported to the ethnic committee of Peking University Third Hospital, which will
- 366 decide whether to continue or terminate this trial.
- 367

# 368 Frequency and plans for auditing trial conduct

- 369 The principal and lead investigators will meet biweekly to review the progress of the trial and
- 370 audit the trial conduct.
- 371

| 372 | Plans for communicating | j important protoco | l amendments to | relevant parties | (e.g. trial |
|-----|-------------------------|---------------------|-----------------|------------------|-------------|
|-----|-------------------------|---------------------|-----------------|------------------|-------------|

- 373 participants, ethical committees)
- 374 Any amendments to the study protocol must receive approval from the Ethics Committee of
- 375 Peking University Third Hospital. All participants, their parents, PE teachers, and research
- 376 staff will be promptly informed of any changes made to the study protocol. In case of a
- 377 potential COVID-19 outbreak in the school, the intervention will be suspended and resumed in
- 378 compliance with the school and government policies.
- 379

### 380 **Dissemination plans**

381 The results of this trial will be presented at domestic and international conferences and

382 published in peer-reviewed academic journals. Progress and final reports will be submitted to

383 the funding agency and regulatory bodies.

384

### 385 Conclusions

- 386 The present trial will provide a novel multilevel-coordinated exercise intervention targeting
- 387 obese and overweight children. This study aims to yield quantitative and qualitative results
- 388 which will shed light on the effectiveness of multi-level exercises with various intensities in
- 389 promoting cardiometabolic fitness and reducing adiposity in overweight and obese

| 390 | school-aged children. Moreover, this study will utilize a multi-omic approach and systematic   |
|-----|--|
| 391 | epidemiological design to investigate the possible molecular mechanisms of the exercise        |
| 392 | intervention in modulating adiposity at multiple levels. The outcomes of this trial will offer |
| 393 | clinical evidence for establishing bodyweight management guidelines for Chinese schools.       |
| 394 |  |
| 395 | Trial status   |
| 396 | This trial has been registered at ClinicalTrials.gov with the identifier NCT04984005.          |
| 397 |  |
| 398 | Acknowledgements   |
| 399 | Our special thanks go to the children, parents and physical education teachers who are         |
| 400 | participating in this study. We also acknowledge the ethics committee of Peking University     |
| 401 | Third Hospital. We thank Huawei Technologies Co., Ltd. for donating the smartwatch and the     |
| 402 | technical support of the Huawei Research platform to this study. We also thank Beijing BOE     |
| 403 | Health Technology Co., Ltd. for providing the equipment for the physical examination.          |
| 404 |  |
| 405 | Author contributions   |
| 406 | YZ, CL, TH, and MX contributed to conception and design of the study. JW, YL, and HY           |
| 407 | organized the database. YZ, CL, TC, CF, WW, YL, HW, YX, WZ, CR LC, XF, DF, HH, XY, and         |
| 408 | TH performed the study. YZ and CL wrote the first draft of the manuscript. All authors         |
| 409 | contributed to manuscript revision, read, and approved the submitted version.                  |
| 410 |  |

411 Funding

- 412 This trial is funded by National Key Research and Development Program (grant numbers:
- 413 2020YFA0803803 and 2020YFA0803800) and CAMS Innovation Fund for Medical Sciences
- 414 (grant number: 2021-I2M-5-003).

415

# 416 Availability of data and materials

- 417 Study data will be available from the principal investigator upon reasonable request and will
- 418 not be made publicly available.

419

### 420 Ethics approval and consent to participate

- 421 This study has been approved by the ethics committee of Peking University Third Hospital
- 422 (ethnic approval number 2021-283-08).
- 423
- 424 Consent for publication
- 425 Not applicable.

426

- 427 Competing interests
- 428 The authors declare no competing interests.
- 429

### 430 References

- 431 1. Jebeile H, Kelly AS, O'Malley G, et al. Obesity in children and adolescents: epidemiology, causes,
  432 assessment, and management. *The lancet Diabetes & endocrinology* 2022;10(5):351-65. doi:
- 433 10.1016/s2213-8587(22)00047-x [published Online First: 2022/03/07]
- 434 2. Di Cesare M, Sorić M, Bovet P, et al. The epidemiological burden of obesity in childhood: a worldwide
  435 epidemic requiring urgent action. *BMC Med* 2019;17(1):212. doi: 10.1186/s12916-019-1449-8
  436 [published Online First: 2019/11/26]

| 437 | 3. Gupta N, Goel K, Shah P, et al. Childhood obesity in developing countries: epidemiology,               |
|-----|---|
| 438 | determinants, and prevention. Endocr Rev 2012;33(1):48-70. doi: 10.1210/er.2010-0028                      |
| 439 | [published Online First: 2012/01/14]  |
| 440 | 4. Liu Z, Gao P, Gao AY, et al. Effectiveness of a Multifaceted Intervention for Prevention of Obesity in |
| 441 | Primary School Children in China: A Cluster Randomized Clinical Trial. JAMA Pediatr                       |
| 442 | 2022;176(1):e214375. doi: 10.1001/jamapediatrics.2021.4375 [published Online First:                       |
| 443 | 2021/11/09]   |
| 444 | 5. Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. The lancet Diabetes &        |
| 445 | endocrinology 2021;9(6):373-92. doi: 10.1016/s2213-8587(21)00045-0 [published Online First:               |
| 446 | 2021/05/23]   |
| 447 | 6. Flynn JT, Urbina EM, Brady TM, et al. Ambulatory Blood Pressure Monitoring in Children and             |
| 448 | Adolescents: 2022 Update: A Scientific Statement From the American Heart Association.                     |
| 449 | Hypertension (Dallas, Tex : 1979) 2022;79(7):e114-e24. doi: 10.1161/hyp.000000000000215                   |
| 450 | [published Online First: 2022/05/24]  |
| 451 | 7. Myette RL, Feber J, Blinder H, et al. Blood pressure variability in children with obesity and          |
| 452 | sleep-disordered breathing following positive airway pressure treatment. Pediatr Res                      |
| 453 | 2022;92(3):810-15. doi: 10.1038/s41390-021-01841-8 [published Online First: 2021/11/18]                   |
| 454 | 8. Chrysaidou K, Kotsis V, Chainoglou A, et al. Impact of ambulatory SBP and overweight on executive      |
| 455 | function performance in children and adolescents. Journal of hypertension 2020;38(6):1123-30.             |
| 456 | doi: 10.1097/hjh.000000000002371 [published Online First: 2020/05/07]                                     |
| 457 | 9. Twig G, Tirosh A, Leiba A, et al. BMI at Age 17 Years and Diabetes Mortality in Midlife: A Nationwide  |
| 458 | Cohort of 2.3 Million Adolescents. Diabetes care 2016;39(11):1996-2003. doi:                              |
| 459 | 10.2337/dc16-1203 [published Online First: 2016/10/14]  |
| 460 | 10. Twig G, Yaniv G, Levine H, et al. Body-Mass Index in 2.3 Million Adolescents and Cardiovascular       |
| 461 | Death in Adulthood. N Engl J Med 2016;374(25):2430-40. doi: 10.1056/NEJMoa1503840                         |
| 462 | [published Online First: 2016/04/14]  |
| 463 | 11. Martin A, Booth JN, Laird Y, et al. Physical activity, diet and other behavioural interventions for   |
| 464 | improving cognition and school achievement in children and adolescents with obesity or                    |
| 465 | overweight. Cochrane Database Syst Rev 2018;3(3):Cd009728. doi:   |
| 466 | 10.1002/14651858.CD009728.pub4 [published Online First: 2018/03/03]                                       |
| 467 | 12. Cadenas-Sanchez C, Idoate F, Cabeza R, et al. Effect of a Multicomponent Intervention on Hepatic      |
| 468 | Steatosis Is Partially Mediated by the Reduction of Intermuscular Abdominal Adipose Tissue in             |
| 469 | Children With Overweight or Obesity: The EFIGRO Project. Diabetes care 2022;45(9):1953-60.                |
| 470 | doi: 10.2337/dc21-2440 [published Online First: 2022/09/01]   |
| 471 | 13. Wang Y, Wang K, Du M, et al. Maternal consumption of ultra-processed foods and subsequent risk        |
| 472 | of offspring overweight or obesity: results from three prospective cohort studies. Bmj                    |
| 473 | 2022;379:e071767. doi: 10.1136/bmj-2022-071767 [published Online First: 2022/10/06]                       |
| 474 | 14. Hargreaves D, Mates E, Menon P, et al. Strategies and interventions for healthy adolescent growth,    |
| 475 | nutrition, and development. Lancet (London, England) 2022;399(10320):198-210. doi:                        |
| 476 | 10.1016/s0140-6736(21)01593-2 [published Online First: 2021/12/03]  |
| 477 | 15. Mead E, Brown T, Rees K, et al. Diet, physical activity and behavioural interventions for the         |
| 478 | treatment of overweight or obese children from the age of 6 to 11 years. Cochrane Database                |
| 479 | Syst Rev 2017;6(6):Cd012651. doi: 10.1002/14651858.Cd012651 [published Online First:                      |
| 480 | 2017/06/24]   |

- 16. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for
  protocols of clinical trials. *Bmj* 2013;346:e7586. doi: 10.1136/bmj.e7586 [published Online First:
  2013/01/11]
- 484 17. Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in
  485 patients with cardiovascular disease. *European heart journal* 2021;42(1):17-96. doi:
- 486 10.1093/eurheartj/ehaa605 [published Online First: 2020/08/30]
- 487 18. Blair SN, Gibbons LW. Guidelines for exercise testing and prescription. *Journal of Cardiopulmonary* 488 *Rehabilitation and Prevention* 1986;6(8):315-16.
- 489 19. Yang Y. China Food Composition Table2002.
- 20. Zhang F, Wan Y, Zuo T, et al. Prolonged Impairment of Short-Chain Fatty Acid and L-Isoleucine
   Biosynthesis in Gut Microbiome in Patients With COVID-19. *Gastroenterology*
- 492 2022;162(2):548-61.e4. doi: 10.1053/j.gastro.2021.10.013 [published Online First: 2021/10/24]
- 493 21. Yuan M, Breitkopf SB, Yang X, et al. A positive/negative ion-switching, targeted mass
- 494 spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue.
- 495 Nat Protoc 2012;7(5):872-81. doi: 10.1038/nprot.2012.024 [published Online First: 2012/04/14]
- 496 22. China BNHCotPsRo. WS/T 586—2018, Screening for overweight and obesity among school-age
   497 children and adolescents, 2018.

498

|               | Bc            | bys     | Girls         |         |  |  |  |
|---------------|---------------|---------|---------------|---------|--|--|--|
| Age, years    | Overweight    | Obesity | Overweight    | Obesity |  |  |  |
| 8.0 - < 8.5   | 17.8 - < 19.7 | ≥ 19.7  | 17.6 - < 19.4 | ≥ 19.4  |  |  |  |
| 8.5 - < 9.0   | 18.1 - < 20.3 | ≥ 20.3  | 18.1 - < 19.9 | ≥ 19.9  |  |  |  |
| 9.0 - < 9.5   | 18.5 - < 20.8 | ≥ 20.8  | 18.5 - < 20.4 | ≥ 20.4  |  |  |  |
| 9.5 - < 10.0  | 18.9 - < 21.4 | ≥ 21.4  | 19.0 - < 21.0 | ≥ 21.0  |  |  |  |
| 10.0 - < 10.5 | 19.2 - < 21.9 | ≥ 21.9  | 19.5 - < 21.5 | ≥ 21.5  |  |  |  |
| 10.5 - < 11.0 | 19.6 - < 22.5 | ≥ 22.5  | 20.0 - < 22.1 | ≥ 22.1  |  |  |  |
| 11.5 - 12.0   | 19.9 - < 23.0 | ≥ 23.0  | 20.5 - < 22.7 | ≥ 22.7  |  |  |  |

| 500 | Table 1 Age- and sex-s  | necific BMI cutoff  | points of childhood   | overweight and | ohosity <sup>22</sup> |
|-----|-------------------------|---------------------|-----------------------|----------------|-----------------------|
| 500 | Table 1. Aye- and sex-s | pecilic Divil cuton | points or criticitoou | overweight and | JUCSILY.              |

501

|                                      | Enrolment | Allocation | Run-in |   | Intervention |   |    | Follow-up |    |    |
|--------------------------------------|-----------|------------|--------|---|--------------|---|----|-----------|----|----|
| Timepoint, week                      | -         | -          | 1      | 2 | 4            | 8 | 12 | 24        | 36 | 48 |
| Enrolment                            |           |            |        |   |              |   |    |           |    |    |
| Informed consent                     | x         |            |        |   |              |   |    |           |    |    |
| Eligibility screen                   | x         |            |        |   |              |   |    |           |    |    |
| Baseline assessment                  | x         |            |        |   |              |   |    |           |    |    |
| Allocation                           |           | x          |        |   |              |   |    |           |    |    |
| Intervention                         |           |            |        |   |              |   |    |           |    |    |
| Light-intensity exercise             |           |            | x      | x | x            | х | x  |           |    |    |
| Moderate-intensity exercise          |           |            | x      | x | x            | х | x  |           |    |    |
| Intermittent vigorous exercise       |           |            | х      | x | x            | х | x  |           |    |    |
| Assessment                           |           |            |        |   |              |   |    |           |    |    |
| Adiposity                            |           | x          |        |   | x            | х | x  | х         | x  | х  |
| Sexual hormones                      |           | x          |        |   | x            | x | x  | x         | x  | х  |
| Body compositions                    |           | x          |        |   | x            | х | x  | х         | х  | х  |
| Cardiopulmonary function             |           | x          |        |   | x            | х | x  | х         | x  | x  |
| Biochemical measurement              |           | x          |        |   | x            | x | x  | x         | x  | x  |
| Exercise performance                 |           | x          |        |   |              |   | x  |           |    | x  |
| Hepatic hemodynamic index            |           | x          |        |   |              |   | x  |           |    | х  |
| Bone mineral density                 |           | x          |        |   |              |   | x  |           |    | х  |
| Inflammatory biomarkers              |           | x          |        |   |              |   | x  |           |    | х  |
| Thyroid function                     |           | x          |        |   |              |   | х  |           |    | х  |
| Oxidative stress biomarkers          |           | x          |        |   |              |   | x  |           |    | х  |
| Oral and gut microbiota              |           | x          |        |   |              |   | x  |           |    | х  |
| Blood and faecal metabolomics        |           | x          |        |   |              |   | x  |           |    | х  |
| Attention performance                |           | x          |        |   |              |   | x  |           |    | х  |
| Sleep quality                        |           | x          |        |   |              |   | x  |           |    | х  |
| Diets and nutrients                  |           | x          |        |   |              |   | x  |           |    | х  |
| Whole genome sequencing              |           | x          |        |   |              |   | x  |           |    | х  |
| Viromics                             |           | x          |        |   |              |   | x  |           |    | х  |
| Proteomics                           |           | x          |        |   |              |   | x  |           |    | х  |
| Volatile organic compounds in breath |           | x          |        |   |              |   | x  |           |    | х  |
| Anthropometric measurement of the    |           | v          |        |   |              |   |    |           |    |    |
| parents                              |           | ^          |        |   |              |   | ^  | ^         |    |    |
| Whole genome sequencing of the       |           |            |        |   |              |   |    | v         |    |    |
| parents;                             |           |            |        |   |              |   |    | Â         |    |    |
| Disease history of the parents       |           |            |        |   |              |   |    | x         |    |    |

# 503 **Figure 1** Schedule of enrollment, allocation, interventions, and assessments.